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This work aimed to characterize the mammary gland pharmacokinetics of cefquinome
after an intramammary administration and integrate pharmacokinetic/pharmacodynamic
model. The pharmacokinetic profiles of cefquinome in gland tissue were measured
using high performance liquid chromatograph. Therapeutic regimens covered various
dosages ranging from 25 to 800 µg/gland and multiple dosing intervals of 8, 12, and
24 h. The in vivo bacterial killing activity elevated when dosage increased or when dosing
intervals were shortened. The best antibacterial effect was demonstrated by a mean 1.5
log10CFU/gland visible count reduction. On the other hand, the results showed that the
percentage of time duration of drug concentration exceeding the MIC during a dose
interval (%T > MIC) was generally 100% because of the influence of drug distribution
caused by the blood-milk barrier. Therefore, pharmacokinetic/pharmacodynamic
parameter of the ratio of area under the concentration-time curve over 24 h to the MIC
(AUC0−24/MIC) was used to describe the efficacy of cefquinome instead of %T > MIC.
When the magnitude of AUC0 24/MIC exceeding 16571.55 h mL/g,− · considerable
activity of about 1.5 log10CFU/g gland bacterial count reduction was observed in vivo.
Based on the Monte Carlo simulation, the clinical recommended regimen of three
infusions of 75 mg per quarter every 12 h can achieve a 76.67% cure rate in clinical
treatment of bovine mastitis caused by Staphylococcus aureus infection.
Keywords: dose assessment, PK/PD, Monte Carlo simulation, cefquinome, mastitis
INTRODUCTION
Staphylococcus aureus is a common Gram-positive bacterium that frequently causes a variety of
infections in humans and animals and is the primary pathogen responsible for bovine mastitis.
S. aureus mastitis can lead to significant economic loss to the dairy industry due to the deterioration
of milk quality, veterinary medicine expenses, and prohibitive labor costs (Gruet et al., 2001).
According to the clinical features, intramammary infection (IMI) is classified as clinical and
subclinical mastitis. Clinical mastitis is acute and severe and may cause cow’s death. While
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subclinical mastitis is generally not lethal, but can lead to huge
financial losses. S. aureus can be isolated from the mammary
gland (MG) tissue of all forms of mastitis because these organisms
are capable of hiding in host phagocytes and mammary epithelial
cell to avoid antibiotic effect (Hebert et al., 2000).
Cefquinome is a semisynthetic β-lactam antibiotic and
fourth-generation cephalosporin developed for use in veterinary
medicine. It is stable to common plasmid- and chromosomally
mediated β-lactamases. For example, cefquinome showed higher
ability to treat the equine infection than penicillin G and
gentamicin (Widmer et al., 2009). When using cefquinome
in treatment of IMI diseases, a considerable therapeutic effect
is found: the clinical persistence and recurrence of bovine
mastitis are reduced during lactation; and the treated cows
are less likely to develop clinical mastitis in the dry period
(Bradley et al., 2011; Swinkels et al., 2013). Cefquinome can
be administered by a parenteral route, intramammary infusion,
or parenteral injection combined with intramammary infusion
in China. The intramammary treatment may acquire a higher
cure rate compared with systemic administration (Shpigel et al.,
2006).
With regard to optimization of therapy regimen,
pharmacokinetic and pharmacodynamic (PK/PD) model is
an advanced approach concurrently analyzing the time course
and the antibacterial effectiveness of a drug. The PK/PD
analysis may further elucidate an inadequate daily dose or
extended dosing interval accompanied under traditional dosing
regimen determination. In our previous work, the PK/PD
characteristics, especially in the blood, were studied against the
S. aureus in a mouse mastitis model following an intramammary
administration (Yu et al., 2016). However, we wondered how
the drug concentrations would be in local MG and if it might
be better to use MG PK data to optimize the dosage, given that
in some organs (like brain or MG) drug distribution become
much more complex due to the special anatomic structures or
transport barriers.
The objective of this work was to characterize the PK of
cefquinome in MG tissue after an intramammary infusion and
integrate PK/PD model of MG tissue. In addition, analysis
of surrogate PK/PD indexes required for different levels of
antibacterial activity was estimated using the inhibitory sigmoid
Emax PD model. Furthermore, we aimed to extrapolate the PK/PD
profiles to bovine mastitis treatment and assess the clinical
therapeutic regimen using Monte Carlo simulation.
MATERIALS AND METHODS
Bacterial Strains, Reagents, and Animals
SStaphylococcus aureus isolates from bovine mastitis was the
same population reported by our previous work (Yu et al., 2016),
of which the MIC90 was 0.5 µg/ml. A similar sensitivity of these
isolates to cefquinome was supported by determining the time-
killing curves in vitro (Supplementary Figure S1). Therefore,
isolate JP41 of MIC equally to 0.5 µg/ml was chosen randomly
for the succeeding trials. The stock solution of cefquinome
(Qilu Animal Health Products CO., Ltd, Shandong, China) was
prepared in sterile water at 40,000 µg/mL and stored at −20◦C
until use.
Lactating mice (purchased from Vital River Laboratories,
Beijing, China) with body weight of 35–45 g, breeding in a
special-pathogen-free (SPF) environment with a 12:12 light: dark
circle were used in this study. Experiments were conducted
on the L4 (fourth on the left) and R4 (fourth on the right)
abdominal glands, which have the biggest size among the whole
five pairs of mouse glands and can be harvested easily. The animal
studies were approved by the Animal Use and Care Committee
of South China Agricultural University. During the in vivo
procedures, guidelines of American Association for Accreditation
of Laboratory Animal Care (Institute of Laboratory Animal
Research, Commission on Life Sciences, National Research
Council, 1996) had been properly respected.
Calculation of PK in MG Tissue
Firstly, three healthy CD-1 lactating mice were employed to
evaluate the influence of drug distribution on the concentrations
of L4 and R4 glands. In brief, 1–2 h following removal of
10–12 day-old offspring, lactating mice were intramammary
administrated to just one abdominal gland (L4 or R4). Through
a small cut under a teat, 100 µL of cefquinome (1000 µg/mL)
was injected into the exposed udder canal using a 32-gage
blunt needle. Both the processed and non-treated glands were
harvested at time points of 0.08, 0.17, 0.25, 0.5, 0.75, 1, 2, 4, 8,
12, and 24 h after administration. Then drug concentrations in
L4 and R4 abdominal glands were measured.
Secondly, MG tissue PK study was performed at a single dose
of 25, 50, 100, or 200 µg/gland intramammary infusion into both
the L4 and R4 glands (each gland as an individual), 5 mice a
group (i.e., n = 10 for glands). The administrative procedure
was described above. The R4 and L4 MG samples were harvested
at 0.08, 0.17, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, and 24 h after
administration.
All the MG samples were processed and analyzed for
cefquinome concentrations, and the extracting method and
high performance liquid chromatograph (HPLC) condition were
described below.
Determination of Cefquinome in MG
Tissue
The gland tissues were homogenized and processed based on
the previous report with some modification (Sørensen and Snor,
2000). Briefly, a weight of 0.5 g tissue sample was transferred
to a 15 mL polypropylene centrifuge tube and a volume of
5 mL acetonitrile was added. The mixture was shaken vigorously
for 2 min using Lab dancer machine (IKA, German) and
then centrifuged (Thermo Fisher Scientific, USA) at 5,000 g
for 10 min. The supernatant was removed and tissue in the
bottom was extracted once more again with 2 mL acetonitrile.
The supernatant twice extracted was evaporated under a gentle
steam of nitrogen (MIULAB, Hangzhou, China) at 38–40◦C. The
extract was diluted with 5 ml of water and cleaned up by tC18
solid-phase extraction (SPE) cartridge (Waters CO., USA). The
analytes were eluted with 2 mL acetonitrile and evaporated under
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a stream of nitrogen at 38–40◦C. The pellet was redissolved in
1 mL ultrapure water and filtered through a 0.22 µm syringe
filter for HPLC analysis (Ultimate 3000, Dionex), equipped with
a RP18 column (4.6 mm × 150 mm, 5 µm; Waters Co., USA).
The injection volume was 50 µl, and column temperature was
maintained at 30◦C. The mobile phase consisted of acetonitrile
and 5 mM ammonium acetate containing 0.1% formic acid
(v/v, 13/87) provided as an isocratic elution with a flow rate of
250 µl/min. The total run time was 7 min.
The extraction recovery (RE) and coefficient of variation (CV)
of intra-assay and inter-assay were calculated. Samples of 10, 20,
and 50 µg/gland were prepared by adding the standard work
solution directly onto the blank gland tissue. After a 30-min
incubation for mixing, samples were homogenized, processed,
and tested by HPLC as described above. Triple parallels of each
concentration for one trial were performed three times totally.
The formulas of RE and CV were as follows:
RE(%) = CCa × 100% (1)
CV(%) =
√∑n
i=1(xi − x−)/(n− 1)
x−
× 100% (2)
Where C is calculated drug concentration and Ca is added
concentraion; n represents for the repeater, x− is average value
of concentration.
Design of PD Experiments
Three CD-1 lactating mice were employed for each condition
of treatment using the mouse model of S. aureus mastitis
(Brouillette et al., 2005; Yu et al., 2016). Totally, 21 therapeutic
regimens were investigated in this work. The treatment doses
ranged from 25 to 800 µg per gland, and the dosing intervals
were 8, 12, and 24 h, respectively. An overnight culture of
S. aureus JP41 isolates in BHI broth was injected in mice MG
after an appropriate dilution. When bacterial counts reaching
7 log10CFU/gland in gland tissue (∼9 h incubation after
inoculation), cefquinome was administrated to L4 and R4 glands
simultaneously and at the corresponding dosing intervals during
the 24 h experimental circle. After 24 h treatment, three mice in
each group were euthanized for colony count determination (i.e.,
n = 6 for glands). The mice in non-treated control group were
tested before the intramammary administration and after 24 h.
PK/PD Analysis
The cefquinome PK of gland tissue was analyzed using the non-
compartment model and one-compartment with non-absorption
model, respectively, by WinNonlin software (version 5.2.1;
Pharsight, USA). The surrogate markers of antibacterial efficacy,
including the ratio of area under the concentration-time curve
over 24 h to the MIC (AUC0−24/MIC), the percentage of time
duration of drug concentration exceeding the MIC during a dose
interval (%T>MIC) and the ratio of peak concentration divided
by the MIC (Cmax/MIC), were formulated by using in vitro
MIC90 values in broth and in vivo PK parameters obtained after
intramammary administration of cefquinome. The units of Cmax
and AUC in gland tissue were ug/g and hr·ug/g, respectively. The
PK/PD parameters of the entire dosing regimens were obtained
by extrapolation of the PK profiles determined above.
The antimicrobial effect of cefquinome was analyzed applying
the sigmoid Emax model of inhibitory effect, as previously
reported (Zhao et al., 2014), which is defined as
E = Emax − (Emax − Eo)× C
N
e
ECN50 + CNe
(3)
where E is the antibacterial effect, measured as the change in
the bacterial counts (log10CFU/g gland) in the gland sample
after 24 h of treatment compared to the initial colony counts;
Emax is the 1log10CFU/g gland in the drug-free control
sample; E0 is the 1log10CFU24 h/g gland in the test sample
containing cefquinome, when the maximum antibacterial effect
was achieved; Ce is the PK/PD index (AUC0−24/MIC, Cmax/MIC
or %T > MIC for gland tissue); EC50 is the value of PK/PD index
of drug producing 50% of the maximum antibacterial effect; and
N is the Hill coefficient, which describes the steepness of the
concentration-effect curve.
Monte Carlo Simulation
Based on a previous PK study (Li et al., 2014), MIC data
(Yu et al., 2016), and the value of PK/PD target magnitude
in this work, simulation with Crystal Ball Professional V7.2.2
software was performed for 5,000 sessions. The probability of
target attainments (PTAs) of the clinically recommended dose
were investigated here. Based on the previous PK study of
cefquinome in cows, AUC of milk sample was assumed to be
normally distributed in the form of mean values and standard
deviation of 4890.19 ± 1906.98 h·µg/mL (Li et al., 2014). The
probability density functions (PDF) of MIC was custom defined
that frequencies of MIC being 0.25 and 0.5 µg/ml were 0.32 and
0.68, respectively, according to our previous study (Yu et al.,
2016). The target values of AUC/MIC were obtained in this work,
of which 1- or 1.5-log-unit bacterial reduction can be achieved
in vivo.
To assess therapeutic effect of cefquinome, the PDF of AUC
and MIC were the two main components for Monte Carlo
simulation. Random sampling the stochastic variable of specified
PDFs, thousands of estimation of AUC/MIC and its range of
probability will be attained. Then a target value of AUC/MIC was
set to calculate the attainment rate of the corresponding dosing
regimen, which is defined as the PTA.
RESULTS
PK Profiles in Gland Tissues after
Intramammary Administration
The limit of quantification (LOQ) was 50 ng/mL and the limit
of detection (LOD) was 10 ng/mL in MG tissue. The REs for 10,
20, and 50 µg/gland were 95.43 ± 2.16%, 87.86 ± 4.99% and
73.65 ± 3.22%, respectively. In addition, the CVs of intra-assay
and inter-assay are presented in Supplementary Table S1.
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No adverse effects, like death of stress, acute death,
depression, and abnormal behavior, were observed after
intramammary administration. Supplementary Figure S2
shows the concentration-time curves of both glands,
following cefquinome administration into only one MG.
The level of cefquinome in the non-treated gland was
over 100 times lower than in the administrated one and
as low as the LOQ, suggesting that the influence of drug
administration to one side of gland on the concentration
of the other non-dosed side should be negligible in the
same subject. Therefore, we should be able to treat an
individual gland as an independent study sample in the
study design without concerning the inter-gland drug transfer
impact.
Logarithmic concentration-time plots of the MG tissue
data after intramammary administration on both sides of
the fourth gland are displayed in Figure 1. Profiles of PK
in gland tissue are presented in Table 1, being analyzed
via non-compartmental and one-compartmental models,
respectively. The median correlation coefficient (R2) of four
concentration-time curves was equal to 0.93 for the non-
compartment model and 0.94 for the one-compartment
model. Elimination half-life t1/2−MG of 12.44 ± 0.81 and
12.66 ± 0.69 h was calculated, respectively. The AUC0−24,
being analyzed via the one-compartment with non-absorption
model, was slightly higher than the non-compartment model.
The mean residence time (MRTMG) determined by non-
compartment model was 9.09 ± 2.31 h. The eliminating
pattern of cefquinome and the comparable value of PK
parameters obtained by those two Winnonlin models
demonstrated that the PK characteristic in glandular tissue
was eliminated exponentially, or following first-order
kinetics. Therefore, PK features of multiple dosing were
extrapolated from the values obtained in the study described
above.
FIGURE 1 | Semi-logarithmic plot of gland tissue concentration versus
time of cefquinome in CD-1 mice following an intramammary
administration dose of 25, 50, 100, 200 µg/gland. Each time point
represents the arithmetic mean of five mice (for gland tissue, n = 10).
PD Evaluation of Various Dosing
Regimens
The therapeutic activity of cefquinome was evaluated by bacterial
counts (log10CFU/gland) at t = 24 h in mouse model of S. aureus
mastitis. Figure 2 shows antibacterial effects against isolate JP41
of 18 therapeutic regimens, with dosages ranged from 25 to
800 µg/gland at three dosing intervals of 8, 12, and 24 h,
respectively. The minimal dose amounts to prevent the microbial
growth with 24, 12, and 8 h dosing intervals were 100, 50, and
25 µg/gland, respectively. Among the single daily dose groups,
the greatest antibacterial effect was 1.23 log-unit reduction of
bacterial counts when giving the largest dose of 800 µg/gland.
However, when the dose level was exceeding 400 µg/gland and
with 8 or 12 h dosing intervals at the same time, a better
antibacterial activity was observed with 1.5 log10CFU/gland
reductions or more. As the dose increased and the dosing
intervals shorten, the antibacterial effectiveness of cefquinome
was elevated in vivo, exhibiting a declining trend of survival cells
by the end of experimental circle (Figure 2).
Integration of PK/PD Parameters
Simulation of PK/PD data against isolate JP41 demonstrated
a correlation coefficient (R2) of 0.435, 0.7557 and 0.7413
for %T > MIC, AUC0−24/MIC, and Cmax/MIC respectively
(Figure 3). However, cefquinome concentrations in gland
tissue were maintained above the MIC of 0.5 µg/mL all
the time, so the %T > MIC90 was 100% during the 24 h
experimental circle. Therefore, the relationship between gland
tissue PK and PD activity was reflected by the PK/PD
parameter of AUC0−24/MIC90 (h·mL/g) instead. According to
the sigmoid model, the best killing activity (E0) was about
1.5 log10CFU/gland bacterial count reductions using either
AUC0−24/MIC or Cmax/MIC analysis. The Emax and EC50 were
2.03 log10CFU/gland and 2483.88 h·mL/g for AUC0−24/MIC.
The calculated ratios of AUC0−24/MIC to provide 1 and 1.5
log10 CFU/g gland bacterial load drops were 4714.72 and
16571.55 h·mL/g (Table 2).
Monte Carlo Simulation
Figure 4 exhibits the AUC/MIC distribution of three regimens
of 75 mg once, twice and thrice doses. When the target value
of AUC/MIC was set for 1-log-unit decrease, an over 90% PTAs
was calculated following different regimens. However, values
of PTAs for 1.5-log-unit reduction were much lower, which
were 23.12, 60.75, and 76.67% following once, twice and thrice
administrations, respectively (Table 3).
DISCUSSION
Staphylococcus aureus is usually responsible for contagious
mastitis transmitting between cows, as the uninfected quarters
are normally exposed to the pathogen during milking (Gruet
et al., 2001). Cefquinome is effective against S. aureus bovine
IMI generally, considering that most pathogens are susceptible to
this compound with low MIC value (Supplementary Table S2).
The cefquinome MICs in this study are in line with the level
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TABLE 1 | Pharmacokinetics of cefquinome in MG tissue after a single intramammary administration at dose of 25, 50, 100, and 200 µg per gland to CD-1
mice and analyzed by non-compartment model and one-compartment model, respectively.
Variable(units) Intramammary administration dose(µg/gland) (n = 10)
25 50 100 200 Mean ± SD
Non-compartment model
T1/2−MG (h) 12.02 11.79 12.34 13.62 12.44 ± 0.81
AUC0−24−MG (h·µg/g) 439.41 827.80 1334.46 2017.92
MRTMG (h) 9.08 8.94 9.08 10.00 9.09 ± 0.14
R2 (%) 0.8955 0.9793 0.8961 0.9665 0.93 ± 0.045
One-compartment model
T1/2−MG (h) 12.95 11.63 13.06 13 12.66 ± 0.69
AUC0−24−MG (h·µg/g) 585.88 1064.86 1804.91 2756.41
Cmax−MG (µg/g) 31.37 63.49 95.8 146.92
R2 (%) 0.9095 0.9763 0.8949 0.9637 0.94 ± 0.043
T1/2, elimination half-live representing the procedure that cefquinome transfers from gland tissue to blood; R2, correlation of concentration-time curves, MG, mammary
gland. All the parameters are analyzed using five mice (10 glands) average curve data.
FIGURE 2 | Survived strains size of S. aureus wild isolate JP41 after treating with cefquinome at t = 24 h. Eighteen dose regimens comprised seven dose
levels (25, 50, 100, 200, 400, and 800 µg/gland and three intervals (every 8, 12, and 24 h). A mean value of 7.28 log10CFU/gland of initial bacterial load was
represented as dotted line (n = 6 for glands). The limit of detection was shown as full line.
FIGURE 3 | Relationship between PK/PD parameters in gland tissue and drug killing effectiveness (1log10 CFU/gland) of S. aureus JP41 analyzing by
the sigmoid model. The dots represent the antimicrobial effectiveness of cefquinome (E = final log-unit – initial log-unit) and the lines denoting the predicted value
of E which is simulated from the Winnonlin software. The correlation of observed and predicted E value was quite low in %T > MIC section because of the
distribution of %T > MIC (either 100 or 0%), which is not appropriate for PK/PD integration.
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TABLE 2 | The AUC0−24/MIC in MG tissue against S. aureus JP41 using the
inhibitory form Emax sigmoid model after intramammary administration.
Parameter AUC0−24/MIC
Log Emax (log10CFU/gland) 2.03 ± 0.23
Log E0 (log10CFU/gland) −1.98 ± 0.20
Log Emax – Log E0 (log10CFU/gland) 4.01 ± 0.34
EC50 (h·mL/g) 2483.88 ± 405.55
For bacteriostatic action 2557.56 ± 49.55
For 1 log10CFU/gland reduction 4714.72 ± 8.49
For 1.5 log10CFU/gland reduction 16571.55 ± 49.57
Slope (N) 1.05 ± 0.17
The units of AUC0−24/MIC are and h·mL/g, respectively. PK/PD data for %T > MIC
were not available. Bacteriostatic action means no change about bacterial colony
counts after 24 h incubation.
of previous reports for bovine (Schmid and Thomas, 2002).
Considerable activity of cefquinome has been reported against
methicillin resistant S. aureus (MRSA) strains isolated from
swine, chicken and even human (Aarestrup and Skov, 2010;
Wang et al., 2014). MRSA strains were rarely isolated from
clinical mastitis cases of bovine (Chin et al., 1992; Murphy et al.,
1994). However, for pathogens isolated from human patients, the
MICs were much higher ranging from 1 to 16 µg/mL and most
of the isolates carried the mecA gene. Therefore, susceptibility
distribution of cefquinome suggests that this drug has potential to
treat the IMI caused even by either methicillin sensitive S. aureus
(MSSA) or MRSA, which may largely benefit the general public
health.
Histologically, the blood-milk barrier, formed by the close
link of secretory cells at their apex by tight junctions in
lactating udder, is also responsible for the passive transport
of drug between both compartments, namely blood and milk
(Gruet et al., 2001). These objective factors may explain the
situation: when cefquinome is administered to only one gland,
the drug concentration in the non-treated gland is as low as the
LOQ (Figure 2) or not quantifiable. Comparable findings were
reported in bovine in a previous study (Li et al., 2014). Therefore
the influence of R4 drug concentration on L4 concentration or
vice versa is negligible, and both fourth glands (R4 and L4)
are employed and considered as independent study units for
intramammary dosing.
After intramuscular or subcutaneous administration, the
absorption of cefquinome is quick and complete into the
circulation with a high bioavailability (Aarestrup and Skov, 2010;
Zonca et al., 2011). Nevertheless, following intramammary
infusion drug systemic absorption is limited, and drug
concentration in blood is about 0.1 µg/mL in cow (Zonca
et al., 2011; Li et al., 2014). Somehow, in our works, we found
that drug concentration in blood is higher in mouse than in
bovine (Yu et al., 2016). Considering the relative size of MG
tissue, drug transportation from gland canal to blood may
be easier to happen in mouse than in bovine. Even though,
in our mouse study, the concentration in MG tissue is still
much higher than in blood (Yu et al., 2016), which is in line
with the cow blood/gland distribution pattern (Zonca et al.,
2011). The observed very limited systemic absorption from
localized MG dosing is likely because cefquinome, a β-lactam
antibacterial and organic acid with pKa of 2.51 ∼ 2.91, has
limited lipid solubility to penetrate through membranes, such
as the blood-MG barrier, due to its high degree of ionization
in both plasma (pH = 7.4) and milk (pH = 6.5 ∼ 6.8). The
long half-life of elimination (t1/2−MG) of 12.44 ± 0.81 and
12.66 ± 0.69 h calculated respectively using non-compartmental
and one-compartmental models indicated that the concentration
of cefquinome reached a very high level that was maintained for
a very long time in MG tissue. However, the value of t1/2−MG
in mouse model is still somehow longer than that in bovine,
which may be attributed to the variation between species and
different composition of samples (generally milk samples from
bovine). For the consideration of economic reasons, antibiotics
should be selected and given with the shortest withdrawal period
to make the milk qualified for marketing as soon as possible.
Although the elimination of cefquinome from MG tissue was
quite slow and the MRT was about 6–10 h, the residue of
cefquinome in milk samples cannot be detected after 120 h
following intramammary administration (Zonca et al., 2011; Li
et al., 2014).
The killing activity of cefquinome in the current study is
similar to the previous report, in which the first generation
cephalosporins cefalexin, cefalonium, cefapirin, and cefazolin
were investigated to treat the mouse S. aureus mastitis and
a dramatic effectiveness was observed (Demon et al., 2012).
Although a 5-log10CFU count is usually used as the initial
inoculum in vitro killing trials, in this study a much higher
bacterial load of 7.28 log10CFU/gland is employed in order to
simulate an acute and severe IMI. Compared with the previous
work (Yu et al., 2016), treatments of wild pathogens infection may
call for a larger dose or more frequent dosing intervals, regardless
of the fact that the MIC values are the same.
Even given the minimum dose of 25 µg/gland, the
concentration of cefquinome in gland tissue during 24 h
maintains over the MIC value, which provided a %T > MIC of
100% for all the dosing regimens tested in this study. For time-
dependent drugs, antibacterial effectiveness is more closely linked
to the exposed duration of bacteria than the concentrations,
as long as the drug level is over MIC value. The 100% of
%T > MIC means that the time required for killing activity is
abundant during the entire observation period. In this situation,
the correlation of %T > MIC versus the differences of bacterial
counts (log10 CFU/gland) cannot be obtained for modeling
purpose, suggesting that if a %T > MIC would be a preferred
PK/PD driver, a much lower dose level might be needed. Under
the current dosing schedules, AUC0−24/MIC is used instead to fit
the data to the PK/PD models.
TABLE 3 | The PTA of AUC/MIC for 1- or 1.5-log-unit decrease after
intramammary administration in cows.
Dose Regimen PTA (1-log decrease) PTA (1.5-log decrease)
75 mg once 92.80 23.12
75 mg twice 97.14 60.75
75 mg thrice 97.94 76.67
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FIGURE 4 | Frequency distribution plots of AUC/MIC analyzed by Monte Carlo simulation mimicking cefquinome dosing regimens of 75 mg
intramammary infusion once, twice, and three times.
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As indicated in Figure 2, the killing activity of cefquinome
has elevated only slightly when the drug dose over 200 µg/gland,
which suggests the regimens of 200, 400, and 800 µg/gland
may be over dosed schedules in a mouse model. Similar results
are observed in PK/PD sigmoid model (Figure 3) that identical
decrease of colony counts may require quite different doses on the
flat tail of the curve. Therefore, the AUC/MIC indices achieving
a 1- and 1.5-log-unit decrease at the knee points were used as the
target value in the Monte Carlo simulation, which were 4714.72
and 16571.55 h·mL/g, respectively. The recommended dose
regimen of cefquinome for treatment of bovine mastitis was three
infusion of 75 mg per mammary quarter (The European Agency
for the Evaluation of Medicinal Products Veterinary Medicines
and Inspections, 1998), and the PTAs of 75 mg administration
for once, twice, and thrice were estimated. However, narrow
frequency distribution of MIC is a considerable limit of the
Monte Carlo simulation, as the susceptibilities to cefquinome
are mainly concentrated in 0.25–0.5 µg/ml of this population.
According to the previous papers, MIC levels of cefquinome or
ceftiofur, against S. aureus (either mastitis isolates or not), are
varied from 0.25 to 1 µg/ml but mainly distribute at 0.5 µg/ml
(Zonca et al., 2011; Oliveira et al., 2012; Wang et al., 2014),
which are similar to our report. These findings suggested that at
most 76.67% infected mammary quarter could be cured, but not
bacterially eradicated.
In summary, our study indicates that in vivo analysis
of antimicrobials is of utmost importance to improve their
therapeutic potential. This is the first study ever to assess
glandular tissue PK/PD integration for investigating the
effectiveness of cefquinome. Additionally, our data highlight
the impact of anatomical structure (blood-milk barrier) on the
drug distribution and PK characteristics in blood and gland
tissue compartments. The glandular tissue PK/PD simulation
demonstrates that the value of %T > MIC is generally 100%, the
maximum limit in PK/PD principle, following an intramammary
infusion administration. Instead, the AUC0−24/MIC serves as
substitute parameters under these particular conditions of drug,
microbe and local inflammation combination. The magnitude
of PK/PD parameters to achieve a remarkable antibacterial
efficacy is assessed in this study in relation to treat IMI.
The clinical recommended therapeutic regimen can achieve
approximately 76.67% cure rate as predicted by Monte Carlo
simulation.
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FIGURE S1 | In vitro time-killing curves of cefquinome against S. aureus
isolates with initial bacterial load of 7-log-unit.
FIGURE S2 | The concentration-time curves of both glands, following
cefquinome administration into only one MG. The level of cefquinome in the
non-treated gland was over 100 times lower than in the administrated one and as
low as the LOQ, suggesting that the influence of drug administration to one gland
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